Health Care Cost

A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.

This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.

Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.

With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter who controls Congress.

Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.

An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.

Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.

Medicare Advantage exits, rising ACA premiums, a Medicare for America bill, and a Medicaid work rule ruling frame health policy on Election Day.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

Early modeling put sickle cell gene therapy coverage near $0.11 per member per month.

Cost and access, not side effects, drive GLP-1 discontinuation, and obesity should be covered like diabetes, says Fatima Cody Stanford, MD.

Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.